SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

NCT01472887 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi